Researchers discovered that people carrying the APOE ε4 gene variant share a unique immune-related protein signature across their blood, brain, and cerebrospinal fluid—regardless of neurodegenerative disease diagnosis. This signature reveals a fundamental, disease-independent vulnerability linked to APOE ε4, reframing our understanding of genetic risk in conditions like Alzheimer’s, Parkinson’s, ALS, and FTD.